With Three New Partnerships, Adimab Is On Track to Show Discovery Can Pay Off Quickly
This article was originally published in The Pink Sheet Daily
Executive Summary
A growing list of potentially lucrative partnerships has forced a strategic rethink at antibody discovery company Adimab, which plans to return cash to investors in 2011.